Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ACT15104
Previous Study | Return to List | Next Study

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03546907
Recruitment Status : Completed
First Posted : June 6, 2018
Last Update Posted : February 28, 2020
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Sanofi

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Primary Objective:

To investigate effects of SAR440340 (anti-interleukin-33 [IL‑33] monoclonal antibody [mAb]) compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over up to 52 weeks of treatment.

  • Moderate exacerbations are recorded by the Investigator and defined as AECOPD that require either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics.
  • Severe exacerbations are recorded by the Investigator and defined as AECOPD requiring hospitalization, emergency medical care visit or resulting in death.

Secondary Objectives:

To investigate effects of SAR440340 compared with placebo, on improving respiratory function, as assessed by pre‑bronchodilator forced exploratory volume in 1 second (FEV1).

To evaluate effects of SAR440340 compared with placebo, on Post-bronchodilator FEV1.

To evaluate effects of SAR440340 compared with placebo, on duration from baseline to first moderate or severe AECOPD event.

To evaluate effects of SAR440340 compared with placebo, on safety and tolerability.


Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care Drug: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care Drug: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care Drug: Any short-acting β agonist as prescribed by treating physician as standard of care Phase 2

Detailed Description:
Study participation for each patient will be up to a total of 46 weeks to 76 weeks including up to 10 days to 4 weeks of screening, 24 to 52 week treatment period on investigational medical product (IMP), and 20 weeks of post IMP treatment period.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 343 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Actual Study Start Date : July 16, 2018
Actual Primary Completion Date : October 3, 2019
Actual Study Completion Date : February 19, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: SAR440340
Administration of SAR440340 monotherapy injection
 Drug: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care
Pharmaceutical form:Aerosol or Dry Powder inhaler Route of administration: Inhaled

Drug: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care
Pharmaceutical form:Aerosol or Dry Powder inhaler Route of administration: Inhaled

Drug: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care
Pharmaceutical form:Aerosol or Dry Powder inhaler Route of administration: Inhaled

Drug: Any short-acting β agonist as prescribed by treating physician as standard of care
Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: inhaled
Placebo Comparator: Placebo
Administration of matching placebo for injection of SAR440340
 Drug: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care
Pharmaceutical form:Aerosol or Dry Powder inhaler Route of administration: Inhaled

Drug: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care
Pharmaceutical form:Aerosol or Dry Powder inhaler Route of administration: Inhaled

Drug: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care
Pharmaceutical form:Aerosol or Dry Powder inhaler Route of administration: Inhaled

Drug: Any short-acting β agonist as prescribed by treating physician as standard of care
Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: inhaled


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Rate of moderate-to-severe acute Exacerbations in chronic obstructive pulmonary disease (AECOPD) patients [ Time Frame: Over up to 52 weeks treatment period ]
    Annualized rate of moderate-to-severe AECOPD over up to 52 weeks.


Secondary Outcome Measures :
  1. Change in pre-bronchodilator forced expiratory volume in 1 second (FEV1) [ Time Frame: Baseline to Week 16-24 ]
    Average change in pre-bronchodilator FEV1 from Week 16 to Week 24.

  2. Time to first COPD Exacerbation [ Time Frame: Up to 52 weeks ]
    Time to first moderate or severe AECOPD.

  3. Adverse Events [ Time Frame: Screening up to 72 weeks ]
    Monitor treatment emergent adverse events and serious adverse events.

  4. Change in post-bronchodilator FEV1 [ Time Frame: Baseline to Week 24 ]
    Change from baseline to Week 24 in FEV1 (post-bronchodilator).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria :

  • Participants with a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) for at least 1 year (based on Global Initiative for Chronic Obstructive Lung Disease [GOLD] definition.
  • Participants with moderate-to-severe COPD (post-bronchodilator Forced Expiratory Volume in 1 Second [FEV1]/forced vital capacity [FVC] <70% and post-bronchodilator FEV1 % predicted <80%, but ≥30%).
  • Participants with COPD Assessment Test (CAT) score ≥10 at Screening
  • Participants with reported history of signs and symptoms of chronic bronchitis (chronic productive cough for 3 months in the year up to screening in a patient in whom other causes of chronic cough [e.g., gastroesophageal reflux, chronic rhinosinusitis, bronchiectasis] have been excluded).
  • Participants with a documented history (eg. medical record verification) of ≥2 moderate exacerbations or ≥1 severe exacerbation within the year prior to screening. A moderate exacerbation is defined as an acute exacerbation of COPD (AECOPD) requiring systemic corticosteroids (oral, intravenous, or intramuscular) and/or treatment with antibiotics (however, use of antibiotics alone does not qualify as a "moderate exacerbation" unless documentation is available that use of antibiotics was necessary for treatment of worsening symptoms of COPD). A severe exacerbation is defined as an AECOPD that required a hospitalization.
  • Participants with Standard of Care background therapy, for 3 months and at a stable dose for at least 1 month, including either:
  • Double therapy: Long acting beta agonist (LABA) + Long acting muscarinic agonist (LAMA) or inhaled corticosteroid (ICS) + LABA or ICS + LAMA.

or

  • Triple therapy: LABA + LAMA +ICS.
  • Current or former smokers with a smoking history of ≥10 packs/year.

Exclusion criteria:

  • Concomitant severe diseases or diseases for which the use of Inhaled Corticosteroids (ICS) (e.g., active pulmonary tuberculosis, etc.) or Long Acting Beta Agonists (LABA) are contraindicated (e.g., diagnosis of a history of significant cardiovascular diseases, insulin-dependent diabetes mellitus, hyperthyroidism, thyrotoxicosis, pheochromocytoma, hypokalemia).
  • Use of injectable glucocorticosteroids or oral systemic glucocorticosteroids within previous 1 month or more than 4 courses of IV glucocorticosteroids within the previous 6 months
  • Participants with Bronchial thermoplasty procedure (up to 3 years prior to Visit 1)
  • A current diagnosis of asthma according to the Global Initiative for Asthma (GINA) guidelines.
  • Significant pulmonary disease other than COPD (e.g., lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, eosinophilic granulomatosis with polyangiitis, significant sleep apnea on Bilevel Positive Airway Pressure, etc) or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
  • Diagnosis of α-1 anti-trypsin deficiency.
  • Advanced COPD with need for chronic (>15 hours/day) oxygen support.
  • Participant with a moderate or severe Acute Exacerbation of COPD event within previous 4 weeks
  • A participant who has experienced an upper or lower respiratory tract infection within previous 4 weeks
  • Prior history of or planned pneumonectomy or lung volume reduction surgery.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03546907


Locations
Show Show 83 study locations
Sponsors and Collaborators
Sanofi
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT03546907    
Other Study ID Numbers: ACT15104
2017-003290-34 ( EudraCT Number )
U1111-1194-2134 ( Other Identifier: UTN )
First Posted: June 6, 2018    Key Record Dates
Last Update Posted: February 28, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Muscarinic Agonists
 Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs